Protagenic Change To Netincome from 2010 to 2024

PTIX Stock  USD 0.50  0.02  3.85%   
Protagenic Therapeutics Change To Netincome yearly trend continues to be fairly stable with very little volatility. Change To Netincome will likely drop to about 899.4 K in 2024. During the period from 2010 to 2024, Protagenic Therapeutics Change To Netincome regression line of annual values had r-squared of  0.72 and arithmetic mean of  755,185. View All Fundamentals
 
Change To Netincome  
First Reported
2016-12-31
Previous Quarter
238.8 K
Current Value
226.5 K
Quarterly Volatility
155.2 K
 
Covid
Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.8 K, Interest Expense of 87.3 K or Selling General Administrative of 1.1 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0 or PTB Ratio of 1.11. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Protagenic Therapeutics Correlation against competitors.
For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.

Latest Protagenic Therapeutics' Change To Netincome Growth Pattern

Below is the plot of the Change To Netincome of Protagenic Therapeutics over the last few years. It is Protagenic Therapeutics' Change To Netincome historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Change To Netincome10 Years Trend
Slightly volatile
   Change To Netincome   
       Timeline  

Protagenic Change To Netincome Regression Statistics

Arithmetic Mean755,185
Geometric Mean231,126
Coefficient Of Variation84.01
Mean Deviation560,253
Median896,265
Standard Deviation634,440
Sample Variance402.5B
Range1.7M
R-Value0.85
Mean Square Error122.2B
R-Squared0.72
Significance0.000066
Slope120,225
Total Sum of Squares5.6T

Protagenic Change To Netincome History

2024899.4 K
20231.7 M
20211.4 M
20201.4 M
2019549 K
20181.4 M
2017896.3 K

About Protagenic Therapeutics Financial Statements

Protagenic Therapeutics investors use historical fundamental indicators, such as Protagenic Therapeutics' Change To Netincome, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Change To Netincome1.7 M899.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.